

Christopher G Goetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315707/publications.pdf>

Version: 2024-02-01

124
papers

22,229
citations

66343

42
h-index

21540

114
g-index

131
all docs

131
docs citations

131
times ranked

17409
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
2	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
3	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	3.9	2,497
4	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1020-1028.	3.9	1,739
5	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
6	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
7	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	3.9	885
8	Levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2007, 22, 1379-1389.	3.9	422
9	Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. <i>Movement Disorders</i> , 2005, 20, 523-539.	3.9	327
10	The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a008862-a008862.	6.2	266
11	Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007, 22, 179-186.	3.9	249
12	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	5.3	224
13	Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. <i>Movement Disorders</i> , 2008, 23, 690-699.	3.9	219
14	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 141.	9.0	211
15	The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. <i>Movement Disorders</i> , 2008, 23, 2398-2403.	3.9	196
16	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	3.9	171
17	Dystonia rating scales: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 874-883.	3.9	150
18	Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. <i>Movement Disorders</i> , 2012, 27, 1239-1242.	3.9	148

#	ARTICLE	IF	CITATIONS
19	The Malignant Course of "Benign Hallucinations" in Parkinson Disease. Archives of Neurology, 2006, 63, 713.	4.5	147
20	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Movement Disorders, 2018, 33, 208-218.	3.9	138
21	Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Movement Disorders, 2009, 24, 551-556.	3.9	130
22	Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Annals of Neurology, 2008, 64, S81-S92.	5.3	122
23	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	3.9	114
24	Placebo influences on dyskinesia in Parkinson's disease. Movement Disorders, 2008, 23, 700-707.	3.9	111
25	A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Movement Disorders, 2016, 31, 1373-1380.	3.9	111
26	Systematic review of severity scales and screening instruments for tics: Critique and recommendations. Movement Disorders, 2017, 32, 467-473.	3.9	92
27	Hallucinations and sleep disorders in PD. Neurology, 2010, 75, 1773-1779.	1.1	90
28	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Movement Disorders, 2016, 31, 625-631.	3.9	89
29	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Movement Disorders, 2016, 31, 1455-1465.	3.9	87
30	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	10.2	82
31	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	7.4	80
32	Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years. Movement Disorders, 2011, 26, 2196-2200.	3.9	79
33	Which dyskinesia scale best detects treatment response?. Movement Disorders, 2013, 28, 341-346.	3.9	76
34	Assuring interrater reliability for the UPDRS motor section: Utility of the UPDRS teaching tape. Movement Disorders, 2004, 19, 1453-1456.	3.9	73
35	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
36	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. Npj Parkinson's Disease, 2016, 2, .	5.3	61

#	ARTICLE	IF	CITATIONS
37	Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. <i>Movement Disorders</i> , 2008, 23, 1541-1545.	3.9	59
38	I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. <i>Movement Disorders</i> , 2014, 29, 115-117.	3.9	55
39	Initial management of Parkinson's disease. <i>BMJ, The</i> , 2014, 349, g6258-g6258.	6.0	52
40	Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253.	3.9	51
41	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49
42	Teaching program for the movement disorder society's sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). <i>Movement Disorders</i> , 2010, 25, 1190-1194.	3.9	48
43	Official Japanese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 200-212.	1.5	47
44	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	2.2	46
45	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. <i>Annals of Neurology</i> , 2022, 91, 424-435.	5.3	46
46	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
47	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
48	J.-M. Charcot and simulated neurologic disease. <i>Neurology</i> , 2007, 69, 103-109.	1.1	41
49	Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 267-270.	3.9	40
50	Jean-Martin Charcot and his vibratory chair for Parkinson disease. <i>Neurology</i> , 2009, 73, 475-478.	1.1	39
51	New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, S104-9.	3.9	39
52	Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1135-1139.	2.2	38
53	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	3.9	38
54	Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 465-471.	1.5	37

#	ARTICLE	IF	CITATIONS
55	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016, 31, 563-569.	3.9	36
56	Movement Disorder Society's Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. <i>Movement Disorders</i> , 2020, 35, 911-911.	3.9	34
57	Handling missing values in the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 1632-1638.	3.9	33
58	Validation study of the hoehn and yahr scale included in the MDS-UPDRS. <i>Movement Disorders</i> , 2018, 33, 651-652.	3.9	32
59	Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 11-22.	3.9	31
60	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	3.9	31
61	<sc>IPMDS</sc>'s Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the <sc>MDS</sc>'s <sc>UPDRS</sc> and UDysRS. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 97-101.	1.5	30
62	Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 68-77.	1.5	29
63	Scales to evaluate psychosis in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S38-S41.	2.2	27
64	Evaluating Parkinson's disease patients at home: Utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. <i>Movement Disorders</i> , 2008, 23, 1479-1482.	3.9	24
65	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	3.9	23
66	Telemedicine Use for Movement Disorders: A Global Survey. <i>Telemedicine Journal and E-Health</i> , 2018, 24, 979-992.	2.8	22
67	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8.	2.8	21
68	Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011, 26, 2556-2559.	3.9	20
69	Item Response Theory Analysis of the <sc>MDS</sc>'s <sc>UPDRS</sc> Motor Examination: Tremor vs. Nontremor Items. <i>Movement Disorders</i> , 2020, 35, 1587-1595.	3.9	18
70	Chapter 15 Jean-Martin Charcot and the anatomo-clinical method of neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2009, 95, 203-212.	1.8	13
71	Using Cognitive Pretesting in Scale Development for Parkinson's Disease: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Example. <i>Journal of Parkinson's Disease</i> , 2014, 4, 395-404.	2.8	12
72	Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , 2017, 32, 1335-1336.	3.9	12

#	ARTICLE	IF	CITATIONS
73	Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021, 268, 1945-1950.	3.6	12
74	Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. <i>Brain and Behavior</i> , 2021, 11, e2292.	2.2	11
75	Teaching program for the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2009, 24, 1296-1298.	3.9	10
76	Postural Directionality and Head Tremor in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, .	2.0	10
77	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 7-12.	2.2	9
78	Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 416-425.	1.2	9
79	Hold that pose: capturing cervical dystonia's head deviation severity from video. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 684-694.	3.7	9
80	Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 335-342.	4.2	9
81	Does seasonal variation affect hallucinations in PD? a longitudinal study. <i>Movement Disorders</i> , 2006, 21, 863-865.	3.9	8
82	Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. <i>Neurology</i> , 2010, 74, 1739-1742.	1.1	7
83	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257.	3.9	7
84	Attenuated Postprandial GLP-1 Response in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 660942.	2.8	7
85	Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. <i>Movement Disorders</i> , 2021, 36, 2853-2861.	3.9	7
86	Medical-legal issues in Charcot's neurologic career. <i>Neurology</i> , 2004, 62, 1827-1833.	1.1	6
87	Independent Spanish Validation of the Unified Dyskinesia Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 213-218.	1.5	6
88	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117205.	0.6	6
89	Head tremor in cervical dystonia: Quantifying severity with computer vision. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120154.	0.6	6
90	Charcot in Contemporary Literature. <i>Journal of the History of the Neurosciences</i> , 2006, 15, 22-30.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). <i>Movement Disorders</i> , 2017, 32, 1244-1249.	3.9	5
92	Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2016, 31, 1865-1873.	3.9	4
93	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. <i>Journal of Movement Disorders</i> , 2022, 15, 151-155.	1.3	4
94	Jean-Martin Charcot (1825-1893). <i>Journal of Neurology</i> , 2005, 252, 374-375.	3.6	3
95	The Movement Disorder Society and Movement Disorders: A Modern History. <i>Movement Disorders</i> , 2011, 26, 939-946.	3.9	3
96	Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 21.	2.0	3
97	Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?. <i>Movement Disorders</i> , 2021, 36, 1481-1482.	3.9	3
98	Are Virtual Objective Assessments of Fall Risk Feasible and Safe for People with Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 799-804.	1.5	3
99	Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. <i>Movement Disorders</i> , 2022, 37, 1749-1755.	3.9	3
100	Movement disorders: understanding clinical trials. <i>Lancet Neurology</i> , The, 2005, 4, 5-6.	10.2	2
101	Early cinematographic studies of generalized dystonia. <i>Movement Disorders</i> , 2006, 21, 1561-1565.	3.9	2
102	Treating melancholia at home. <i>Neurology</i> , 2013, 80, 1710-1714.	1.1	2
103	Closing the celebration of 200 years of Parkinson's <i>Essay on the Shaking Palsy</i> : Where do we go in the next 200 years?. <i>Movement Disorders</i> , 2017, 32, 1651-1652.	3.9	2
104	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	3.9	2
105	In Support of Electronic Versions of Movement Disorder Society Rating Scales. <i>Movement Disorders</i> , 2021, 36, 270-271.	3.9	2
106	Validation of the Arabic Version of the Movement Disorder Society Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2022, 37, 826-841.	3.9	2
107	Charcot and Pasteur: Intersecting Orbits in French Medicine. <i>Journal of the History of the Neurosciences</i> , 2009, 18, 378-386.	0.9	1
108	Apathy in Parkinson disease. <i>Neurology</i> , 2020, 95, 893-894.	1.1	1

#	ARTICLE	IF	CITATIONS
109	Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. <i>Neuroepidemiology</i> , 2020, 54, 356-362.	2.3	1
110	Remembrance of Things Past: A Critical Step in Changing our Future. <i>Annals of Neurology</i> , 2021, 90, 521-523.	5.3	1
111	Rating scales for medication adherence in people living with Parkinson's disease. <i>JBIEvidence Synthesis</i> , 2021, Publish Ahead of Print, .	1.3	1
112	Two faces of the teacher: Comparing editions of Charcot's <i>Leçons du mardi</i> . <i>Journal of the History of the Neurosciences</i> , 2022, 31, 512-523.	0.9	1
113	Implementation and Outcomes of a Movement Disorder Society-sponsored Peer Reviewing Education and Mentoring Program. <i>Movement Disorders</i> , 2022, 37, 1093-1097.	3.9	1
114	Greeting from the new editors. <i>Movement Disorders</i> , 2004, 19, 1-1.	3.9	0
115	Approach to the patient presenting with parkinsonism. , 2005, , 551-560.		0
116	Neuroleptic-Induced Movement Disorders. , 2008, , 371-387.		0
117	In Memory of Dr. William J. Weiner. <i>Current Treatment Options in Neurology</i> , 2013, 15, 375-376.	1.8	0
118	Babinski's contributions to cerebellar symptomatology: building the basis of the neurological examination. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 973-975.	0.8	0
119	Preface. <i>Movement Disorders</i> , 2015, 30, 1441-1441.	3.9	0
120	Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". <i>Movement Disorders</i> , 2017, 32, 482-482.	3.9	0
121	Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2018, 33, 1189-1190.	3.9	0
122	Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 113-116.	2.2	0
123	Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 186-194.	1.2	0
124	Validation of the Finnish Version of the Unified Dyskinesia Rating Scale. <i>European Neurology</i> , 2021, 84, 444-449.	1.4	0